MEDO Technologies 10-Q: Going Concern Warning, Zero Cash, $400,884 Nine-Month Loss
MDTK has more than doubled off its 52-week low of $370.
Summary
MEDO Technologies reported a $400,884 nine-month loss with zero cash and an explicit going-concern warning, funded entirely by $334,773 of related-party loans. The post-reverse-split shell has 4,486 common shares outstanding and no revenue or operations.
Key Events · Earnings and Guidance · MDTK
-
Going Concern Warning Disclosed
Management states the $395,562 working capital deficit and $117,963,021 accumulated deficit raise substantial doubt about continuing as a going concern for one year, and that its plans do not alleviate that doubt.
-
Zero Cash, Funded by Insider Loans
Cash at September 30, 2026 was $0. Operations were funded by $334,773 of interest-free demand loans, all of it from controlling shareholder Medo Healthcare LLC, whose balance stood at $321,874.
-
Nine-Month Loss Widens to $400,884
Net loss for the nine months ended September 30, 2026 was $400,884 versus $28,582 a year earlier, driven by $400,884 of administrative expenses against no revenue.
-
Reverse Split Leaves 4,486 Shares
A 1-for-100,000 reverse split took effect September 23, 2026, leaving 4,486 common shares outstanding against 500,000,000 authorized; the 10,000,000 Series A preferred shares carry super-voting rights equal to 25,000 common shares each.
Analysis · MDTK · Trade & Services
This first quarterly report since MEDO Healthcare LLC bought the Series A preferred and installed new management shows a shell with no revenue, no cash and no operations. The company lost $400,884 in the first nine months of 2026 against just $28,582 a year earlier, and every dollar of the $334,773 that funded operations came from interest-free demand loans from its controlling shareholder. Auditors' language is explicit: the working capital deficit of $395,562 and accumulated deficit of $117,963,021 raise substantial doubt about the ability to continue as a going concern, and management says its own plans do not alleviate that doubt. The 1-for-100,000 reverse split on September 23, 2026 left only 4,486 common shares outstanding, so any acquisition financing will require issuing a large new block — management itself says it will likely have to hand a controlling stake to target shareholders. The stated plan is to buy pharmaceutical distributors and layer in AI software, but nothing has been acquired yet.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MDTK was trading at $2,100.00 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $370.00 to $36,330.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.